

# BZ FINE PHARMA

MORNINGSTAR ★★

## Factsheet January 2026

### Fund data

Price on January 30, 2026 (CHF)	241.90
High last 12 months (CHF)	254.10
Low last 12 months (CHF)	201.85
Fund volume (CHF mn)	21.78
Volatility over last year	19.4%
Performance since inception	141.9%

### Performance (in %)

	Jan 2026	1 year	2025	2024	2023	2022
CHF A	-3.1	-3.1	4.3	7.7	-7.2	-17.9
EUR A	-0.1	-0.1	5.4	17.2	-1.3	-13.6
EUR T	1.2	1.2	6.7	6.6	-1.5	-13.6

Performance was calculated on the basis of net asset values (NAV).

### General information


Inception	January 15, 2013
All-in-fee	depends on unit class (see Sales prospectus)
Issuance / redemption fee	max. 2%
Issuances / redemptions	daily
ISIN / Valor-Number	
Share class CHF A	LU0695504364 / 141'427'05
Share class EUR A	LU0695506492 / 141'428'14
Share class EUR T	LU0695508431 / 141'425'15
Share class CHF AV	LU1077079306 / 247'874'44
Bloomberg	BZPHAAF LX
Reuters	BZBANK
Domicile	Luxembourg
Legal structure	SICAV, UCITS
Custodian bank	DZ Privatbank S.A.
Fund administrator	IPConcept (Luxemburg) S. A.
Subscriptions	All banks
Fund manager	BZ Bank Aktiengesellschaft
Registered in	AUT, CH, DE, LUX
Representative AUT	Erste Bank der oest. Sparkassen AG
Representative CH	IPConcept (Schweiz) AG
Representative DE	DZ Bank AG
Paying agent	DZ Privatbank S.A.
Paying agent CH	BZ Bank Aktiengesellschaft
Contact	Eggilrain 15 8832 Wilen Tel +41 44 786 66 00 <a href="mailto:peter.rebsamen@bzbank.ch">peter.rebsamen@bzbank.ch</a>

### Fund description

The objective of the investment policy of the BZ Fine Funds – BZ Fine Pharma ("sub-fund") is to achieve appropriate growth in the specific currency of the share class while taking investment risk into consideration. The return yield of the sub-fund must not only preserve the whole of the invested capital but also be at least equal to inflation and produce an attractive actual return. The return should considerably exceed that of fixed-interest and real-estate investments. This sub-fund seeks to benefit from recognized trends in the healthcare sector in the emerging markets as well as the developed nations. Therefore, the investment universe is not limited to a specific geographic region. This sub-fund invests its assets in healthcare companies, such as pharmaceuticals, biotechnology, equipment and services, medical technology, specialist pharmaceuticals and generic products. The investment decisions are based on the fundamental assessment of the companies and not on their market capitalisation or location.

### Monthly performance (in %)<sup>1</sup>


Net asset value (NAV) since January 15, 2013, Share class CHF A



Source: Macrobond

### Portfolio structure by sector

(In % of total assets)



### Risk profile of the Fund

The Fund is appropriate for growth-oriented investors. Due to the composition of the sub-fund assets, there is a high degree of risk but also a high degree of profit potential. The principal risks of the Fund lie in the concentration of the assets in a specific sector. Compared with the financial market for all sectors, bigger differences in market movements and developments may occur in the short and medium term compared with a specific sector of industry, whether due to a different stage in an economic cycle or to sector-specific or political circumstances. There is no guarantee that the investor will achieve a specific income or that the units will be redeemed at a specific price.

DISCLAIMER: The information provided on this factsheet does not constitute an offer. It is for informational purposes only. Past performance is no guarantee of future trends. The sole basis for the purchase of shares is the sales documents (the current sales prospectus, the key information documents, the articles of association and the reports). You can obtain the current version of the sales documents free of charge from the list of information offices.

<sup>1</sup> References to past performance are not an indicator of future results and do not necessarily guarantee a positive performance in the future. The performance data does not take into consideration the fees and costs imposed on the issue and redemption.